NovoBioPharma, Partnership of Top Life Science Experts, Launches
CAMBRIDGE, Mass., June 11, 2013 /PRNewswire/ -- NovoBioPharma, a partnership of experts collaborating with life science organizations to provide comprehensive medical, scientific, regulatory, business and financial advisory services, launched today. The global business is comprised of four principals, all experts in their fields, who partnered to create an entity to help life science companies and institutions to cost-efficiently advance drug, diagnostic and device candidates by leveraging opportunities from conception through clinical development, and ultimately, regulatory approval.
With decades of experience and a global network in all areas of business, finance, drug, diagnostic and device development, NovoBioPharma offers services in capital sourcing and management, business development, intellectual property, quality control, manufacturing, study design, and protocol development. Simply put, NovoBioPharma covers every facet of the risky and costly work of developing life science breakthroughs.
The NovoBioPharma team is:
Bernie Rudnick, MBA, Chief Business Officer, is founder and managing partner of CapGenic Advisors, LLC, and a founding member of several Angel investing groups. Mr. Rudnick has substantial experience investing and guiding investments in entrepreneurial companies; he has led capital formation totaling more than $530 million in the past ten years and $3B during the last 15 years. Mr. Rudnick, a serial entrepreneur, founded, managed and advised numerous companies in the life sciences, including diagnostic, therapeutic and clinical software environments. Mr. Rudnick is experienced in forms of capital formation including angel networks, venture capital funds, SBIR and other government grant programs. He is a graduate of Penn State and Northwood University.
Ira Wallace, MD, MBA is Chief Development Officer for NovoBioPharma. Dr. Wallace has been involved in pharmaceutical, biotech and medical device companies as a CEO, founder, board member and consultant. In addition, Dr. Wallace is experienced in technology transfer and intellectual property strategies and is a founding member and partner in a number of Angel investment groups. A graduate of the University of Pennsylvania, Dr. Wallace earned his medical degree at Drexel Medical School and his MBA at Columbia.
Shahin Gharakhanian MD, Head, Pharmaceutical Medicine, is an infectious diseases and internal medicine trained physician with over 20 years experience in the pharmaceutical industry and clinical practice. His last position was Vice President in the Medicines Development Group/Global R&D at Vertex Pharmaceuticals, Inc. Cambridge MA, USA. In industry, Dr. Gharakhanian has driven: strategic leadership, clinical development and medical affairs. Overall, he has handled projects for twelve different pharmaceutical companies, ten different brands and four drug launches in Asia, Canada, EU and the United States. His most recent major New Drug Application/launch experience was in 2011. Dr. Gharakhanian earned his specialty medical degrees at University of Paris, and trained/practiced in AP-HP, Paris, France, the largest hospital system in Europe and one of the largest in the world.
Andrew D. Luber, PharmD Chief Scientific Officer, is an infectious diseases trained clinical pharmacist/pharmacologist with over 18 years experience working with the pharmaceutical industry as an investigator, key opinion leader, speakers bureau, steering committee and advisory board member. In addition, he has served as a clinical consultant to large and early stage pharmaceutical companies. Dr. Luber has been an investigator in more than 70 clinical trials including four Phase 1a first in human studies and specializes in early stage drug development. Dr. Luber received his doctor of pharmacy at Temple University and did his post-doctoral residencies and research fellowship at the University of California, San Francisco Medical Center and School of Pharmacy.
For more information, visit the website at NovoBioPharma
Contact: Andrew D. Luber, PharmD 1-856-258-0850
More by this Source
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.